Relay Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Relay Therapeutics, Inc. on October 12, 2023. The filing primarily discloses initial clinical data for RLY-4008 (lirafugratinib), an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), presented at the 2023 AACR-NCI-EORTC International Conference. The data pertains to the global Phase 1/2 ReFocus trial in patients with FGFR2-altered solid tumors.
Key Financial Metrics
This filing does not contain specific financial statements, revenue, profit, or cash flow figures. However, management provided an update on liquidity, stating that the Company expects its cash, cash equivalents, and investments to be sufficient to fund its current operating plan into the second half of 2026.
Material Changes and Clinical Data
The filing details significant clinical progress for RLY-4008 as of the August 23, 2023 data cut-off:
- FGFR2 Fusions: In 26 patients, the overall response rate (ORR) was 35% (9 partial responses). 63% of confirmed responders had a duration of response of at least six months. Activity was observed across 11 tumor types, including pancreatic, ovarian, gastric, NSCLC, and breast.
- HR+/HER2- Breast Cancer: Among 10 patients with this subtype, the ORR was 40% (4 partial responses). All responders had a duration of response of at least six months, with one lasting 72 weeks and ongoing. Patients were heavily pre-treated (median of six prior lines).
- FGFR2 Amplifications: In 34 patients, the ORR was 24% (8 partial responses). 43% of confirmed responders had a duration of response of at least six months. Activity was seen in gastric, breast, colorectal, and esophageal tumors.
- FGFR2 Mutations: Three of 24 patients achieved a partial response.
- Safety Profile: Treatment-related adverse events were generally manageable and reversible. No Grade 4 or 5 adverse events were observed. Off-target toxicities like hyperphosphatemia and diarrhea were clinically insignificant.
Guidance, Outlook, and Pipeline Updates
Management provided the following strategic updates and outlook:
- Development Plans: The Company plans to initiate a triplet combination trial with RLY-2608, fulvestrant, and CDK4/6.
- Portfolio Rationalization: The Company decided to pause further development efforts on RLY-2139, its CDK2 inhibitor.
- Cash Runway: Based on current portfolio updates, the Company expects sufficient liquidity to fund operations into the second half of 2026.
- Enrollment Status: Enrollment is complete in the pivotal expansion cohort for FGFR2-fusion cholangiocarcinoma (CCA) patients who have not previously received an FGFR inhibitor.
Investor Verification Checklist
- Verify the specific duration of response data for the 72-week responder in the breast cancer cohort.
- Confirm the timeline for the initiation of the RLY-2608 triplet combination trial.
- Review the detailed safety data and adverse event profiles in the accompanying slide presentation (Exhibit 99.2).
- Assess the impact of pausing RLY-2139 on the overall R&D budget and cash runway projections.
- Monitor upcoming regulatory interactions regarding the pivotal CCA expansion cohort.